INMED PHARMA Symbol: IMLFF

INMED PHARMA

Symbol: IMLFF

Let me start at the beginning...

A diabetes diagnosis was once a veritable death sentence. A century ago the average life expectancy for a 30-year old with diabetes was just four years.

Then a discovery in 1921 changed all that.

A team of Canadian researchers discovered a way to process pig pancreases into a human insulin replacement. That single discovery changed diabetes from death sentence to chronic disease.

Now, turning pig pancreases into human insulin was anything but an efficient or inexpensive process. It took about 5,000 pig pancreases to produce just eight ounces of insulin.

You can imagine how much money, time, and pig pancreases it would take to treat thousands of diabetes sufferers for years. The process was expensive, complicated and time-consuming, but it was also wildly lucrative.

Eli Lilly – based in Indianapolis, Indiana – led the way in manufacturing insulin from animal organs.

The company’s centralized location relative to the majority of American pig farms made it the ideal insulin producer.

Eli Lilly had a dominant position for nearly 60 years and made a fortune at it too.

Of course, big money like that — literally tens of billions of dollars — created big opportunity for small, highly innovative companies.

That’s just what happened too. It created an entirely new era in biotech, leading a small company on a growth trajectory from just two co-founders to a $48 billion takeover, and now another tiny company is following on the exact same trajectory.

The Birth of Big Biotech

For nearly 60 years Eli Lilly grew to dominate the insulin replacement market. However, one company made a discovery in the early 1970s that would risk Eli Lilly’s insulin processing cash cow.

In the early 1970s, then tiny and innovative biotech company found that it could combine strains of E. coli bacteria with human genes to produce what’s called a “biosynthetic insulin.”

The process was better in every way. It was simpler, faster, and, since it was done in a lab instead of by industrial-level processing of pig pancreases, it was far cheaper.

It’s safe to say that without this discovery animal-derived insulin would have been an expensive treatment reserved for only the most severe cases. Within a few years the new biosynthetic insulin nearly replaced all animal pancreas-based insulin and the industry hasn’t looked back.

The global diabetes pandemic has turned that single innovation in the early 1970s into a $35 billion a year industry today. That small company discovered biosynthetic insulin was Genentech. Genentech ended up partnering with Eli Lilly to produce biosynthetic insulin and both companies grew steadily ever since. Eli Lilly is now a $73 billion pharmaceutical giant. Genentech was acquired by Swiss pharmaceutical giant Roche Holdings for $48 billion at the bottom of the credit crisis in early 2009 (right before the biotech sector went on to rise 500% in the following stock market rally). In the end, this single innovation made big money for the giant partner and led the way for a massive fortune for the early founders of the innovative Genentech by solving one simple and expensive problem. Now one tiny biotech company is targeting the exact same thing as Genentech with the booming cannabis industry.

Big Biotech Meets Marijuana

InMed Pharmaceuticals (IMLFF) is a tiny biotech company with an innovative approach that’s set to play a major role in the marijuana boom.

InMed’s run – much like Genentech in the 1970s — is just getting started too.

Marijuana has a long and complicated history in the world.

The plants’ psychedelic properties make it an illegal narcotic in most of the world. It has many side effects. It used to be believed that Long-term use might significantly and negatively affect cognitive functions.

There were also, undoubtedly, some medicinal properties to marijuana too.

Just look at GW Pharmaceuticals (GWPH) to see what I mean.

GW Pharmaceuticals has successfully isolated a particular part of the marijuana plant, one of nearly a hundred “cannabinoids,” which offers those medicinal properties.

The company has discovered, proven, and brought to market a multiple sclerosis treatment that’s approved for use in dozens of countries.

GW Pharmaceuticals has also isolated another cannabinoid which can be effectively and safely used for the treatment of epilepsy that’s in the final stages of trials before getting approval and hitting the market.

The success of GW in developing pharmaceutical drugs from marijuana over the last few years has sent its shares from less than $9 in 2013 to more than $110 in 2016 and earned it a market value of more than $2.9 billion.

Much like Eli Lilly did in the middle of the last century, when it was shipping in millions of animal pancreases in order to produce a few ounces of animal-derived insulin, GW Pharmaceuticals has a big and fundamental problem.

GW Pharmaceuticals has to buy mountains of marijuana from growers to isolate and extract the key ingredients to produce its drugs.

The costs are enormous.

The marijuana industry has to grow millions of plants at a cost of tens of millions of dollars just to get to enough of those one or two vital cannabinoid ingredients that makes GW Pharmaceuticals drugs effective.

It’s costly.

Too costly.

And one company has advanced the technology to bring the same technology that made insulin treatment available to the masses to bring the medicinal properties of marijuana to millions who suffer from common diseases at an affordable price.

Big Biotech Meets Marijuana

InMed Pharmaceuticals (IMLFF) is a tiny company with a single big idea — use biosynthesis to create the cannabinoids found in tiny amounts in naturally grown marijuana.

InMed has developed and patented a technologically advanced process to isolate and the active cannabinoids (those are the parts of the marijuana plant with proven medicinal properties) and produce them biosynthetically.

It’s just like what Genentech discovered in the 1970s when it took a natural and expensive process to produce insulin and made it far better, cheaper, and faster.

That innovative changed the insulin production industry forever and InMed has the potential to do the same...only in marijuana.

InMed’s patented biosynthesis processes can do for GW Pharmaceuticals and the dozens of other cannabinoid-based pharmaceuticals in development that Genentech did for Eli Lilly.

Just like there won’t be endless trainload of pig organs shipped across the central United States, InMed’s biosynthesis process permits the cannabinoids to be developed without having to build, maintain, and fund acres of marijuana farms.

Not to mention, drastically reduce the costs of getting the cannabinoids in the first place.

There couldn’t be a better time to be doing it either.

A True Billionaire-Make Idea

A True Billionaire-

Make Idea

Recent referenda in the United States has propelled marijuana into the mainstream.

There will be all sorts of opportunities in the sector as the marijuana industry grows in the years ahead.

However, InMed Pharmaceuticals (IMLFF) isn’t a regular marijuana stock that’s going to go through the ups and downs of the market, hit endless regulatory hurdles, and get involved in endless political fights.

InMed has targeted a clear and distinct opportunity historically proven to have multi-billion dollar potential.

Looking ahead at companies like GW Pharmaceuticals and many others will have tapped into the medicinal properties which have made marijuana a widely-used healing drug for centuries despite its narcotic properties.

InMed and its patented and proprietary process for creating the building blocks for all these biotech discoveries will go a long way to supplying the critical and costly cannabinoids essential to these pharmaceuticals’ capabilities.

There once was a time when millions of pig pancreases were shipped across the country to create insulin therapies at great expense.

One innovation ended all that and made early investors in Genentech, the company that discovered the process, into billionaires.

Today there are marijuana farms being built out just to supply the tiniest amounts of key cannabinoids to produce marijuana-based pharmaceuticals.

This process will change too thanks to innovations already made by InMed Pharmaceuticals.

Investors looking for a unique way to get on the rapidly unfolding medical marijuana boom with a stock that hasn’t run yet should take a look at InMed Pharmaceuticals (IMLFF) now.

Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimer. This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed inv­estment advisor.